Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
John A. Windsor | M | - |
Auckland University
| 20 Jahre |
Lain Martin | M | - |
Auckland University
| 24 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Larry Ellingson | M | 78 |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | 6 Jahre |
Adam Mikkelsen | M | - |
Auckland University
| 10 Jahre |
Ting Cheung Leung | M | 41 |
Auckland University
| 5 Jahre |
Peter Hu | M | - |
Auckland University
| 5 Jahre |
Shing Hay Cheng | M | 45 |
Auckland University
| 5 Jahre |
John R. Baker | M | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
Garth J. S. Cooper | M | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
Christopher Heaslip | M | - |
Auckland University
| 1 Jahre |
David Alan Pool | M | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | 8 Jahre |
Oliver Tompkins | M | - |
Auckland University
| 4 Jahre |
Vincent Chun Hung Cheung | M | 36 |
Auckland University
| 4 Jahre |
Pip Hobson | F | - |
Auckland University
| 4 Jahre |
Edward Timmins | M | - |
Auckland University
| 3 Jahre |
Kai Jun Sun | F | 41 |
Auckland University
| 4 Jahre |
Chun Yu Lee | M | 46 |
Auckland University
| 4 Jahre |
Chiang Loong Koay | M | 45 |
Auckland University
| 4 Jahre |
Wing Yee Jor | F | 42 |
Auckland University
| 4 Jahre |
Wan Chye Ling | M | 46 |
Auckland University
| 4 Jahre |
Wai O. | F | 46 |
Auckland University
| 4 Jahre |
Amitesh Chand | M | - |
Auckland University
| 5 Jahre |
Han Wang | M | 44 |
Auckland University
| 4 Jahre |
Chi Ling Chow | F | 42 |
Auckland University
| 4 Jahre |
Dai Xing Deng | M | 39 |
Auckland University
| 4 Jahre |
Shayne Shepherd | M | - |
Auckland University
| 3 Jahre |
Ho Yin Lai | M | 45 |
Auckland University
| 4 Jahre |
Yau Chak Leung | M | 38 |
Auckland University
| 4 Jahre |
Kam Hon Chan | M | 41 |
Auckland University
| 4 Jahre |
Chi Wing Wong | M | 43 |
Auckland University
| 4 Jahre |
Robert McDonald | M | - |
Auckland University
| 4 Jahre |
Shahin Maghsoudi | M | - |
Auckland University
| 4 Jahre |
Ngai Cheung Leung | M | - |
Auckland University
| 3 Jahre |
Smith Liam | M | - |
Auckland University
| 4 Jahre |
Sam Oliver | M | - |
Auckland University
| 5 Jahre |
Junjie Hu | M | 39 |
Auckland University
| 4 Jahre |
Xiao Xiao Jie | M | 40 |
Auckland University
| 4 Jahre |
Manish Raj | M | - |
Auckland University
| 4 Jahre |
Zong Han Wu | M | 45 |
Auckland University
| 4 Jahre |
Fei Fei Guo | F | 44 |
Auckland University
| 4 Jahre |
Ka Chon Chao | M | 48 |
Auckland University
| 4 Jahre |
Natalee Taylor | F | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | 6 Jahre |
Rohit Bassi | M | - |
Auckland University
| 3 Jahre |
Alexander Man-Tat Ng | M | 44 |
Auckland University
| 4 Jahre |
Eric Chi Wing Wong | M | 43 |
Auckland University
| 4 Jahre |
Ali Mundakir | M | - |
Auckland University
| 1 Jahre |
Chi Wing Wong | M | 43 |
Auckland University
| 4 Jahre |
Richard Pinfold | M | - |
Auckland University
| 4 Jahre |
Jin Guo | M | 56 |
Auckland University
| 4 Jahre |
Linda Lin | F | - |
Auckland University
| 4 Jahre |
Jack Yeung | M | - |
Auckland University
| 4 Jahre |
Han Guang Tian | M | 43 |
Auckland University
| 1 Jahre |
Michelle Dobson | F | - |
Auckland University
| 4 Jahre |
Drugh Woods | M | - |
Auckland University
| 4 Jahre |
Jonathan Good | M | - |
Auckland University
| 4 Jahre |
Byron Zhen Wang | M | 52 |
Auckland University
| 1 Jahre |
Tze Chung Lam | M | 52 |
Auckland University
| 4 Jahre |
Oliver Weide | M | - |
Auckland University
| 3 Jahre |
Shirley Wu | F | - |
Auckland University
| 4 Jahre |
Siew Ling Lau | F | - |
Auckland University
| 4 Jahre |
Siew Ping Wong | F | - |
Auckland University
| 4 Jahre |
Alexei J. Drummond | M | - |
Auckland University
| 3 Jahre |
Mitali Purohit | F | - |
Auckland University
| 5 Jahre |
Peter Huljich | M | 47 |
Auckland University
| 5 Jahre |
William Norman Birnie | M | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
Lisa Karel | F | - |
Auckland University
| 4 Jahre |
Robert Bartlett Elliot | M | 90 |
Auckland University
| 29 Jahre |
Bart Taylor Colin Campbell | M | 52 |
Auckland University
| 3 Jahre |
John Hood | M | 72 |
Auckland University
| 5 Jahre |
Brent Lawgun | M | - |
Auckland University
| 3 Jahre |
Brent Ogilvie | M | - |
Auckland University
| 7 Jahre |
Lynne Butler | F | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
Yiu Pong Chan | M | 51 |
Auckland University
| 1 Jahre |
Christopher Krueger | M | 56 |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
John Moller | M | 53 |
Auckland University
| 3 Jahre |
Ying Wai Wong | M | 50 |
Auckland University
| 4 Jahre |
Astrid Modrow | F | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | 7 Jahre |
Brendan Cervin | M | - |
Auckland University
| 4 Jahre |
Nicholas Bartlett | M | - |
Auckland University
| 4 Jahre |
Alan Cherrington | M | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | - |
Matt Harvey | M | - |
Auckland University
| 2 Jahre |
Bin Lu | M | 54 |
Auckland University
| 4 Jahre |
Michael Bos | M | - |
Auckland University
| 3 Jahre |
Wei Dong Qu | M | 57 |
Auckland University
| 1 Jahre |
Victor Obolonkin | M | - |
Auckland University
| 4 Jahre |
Nick Whitehead | M | - |
Auckland University
| 4 Jahre |
Bhagavan Vedant Das | M | - |
Auckland University
| 1 Jahre |
Kai Woon Tee | M | 49 |
Auckland University
| 4 Jahre |
Zhi Hao Liang | M | 47 |
Auckland University
| 4 Jahre |
Alex Leung | M | 45 |
Auckland University
| 4 Jahre |
Robert Chew | M | 67 |
Auckland University
| 1 Jahre |
Ben Gracewood | M | - |
Auckland University
| 6 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Neuseeland | 82 | 89,13% |
Vereinigte Staaten | 10 | 10,87% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sally D. Poppitt
- Persönliches Netzwerk